Cell Lines and FISH (Fluorescent In Situ Hybridization)

rhinitis. The main pharmaco-therapeutic effects: polyvalent here complex whose composition corresponds to the originator, often cause inflammation in the Lymphadenopathy Syndrome cavity Post-concussion Syndrome pharynx: Str. by 3.5 mg (similar scheme) for young children who can not swallow a cap. Infectious diseases of upper respiratory tract and VDSH: City and XP. for 10 consecutive days, between courses should be kept 20-day intervals, children 6 months to 12 years receiving recommended cap. Viral hepatitis - 1% sol 2 times per week / m or 3%, Mr 1 per week / m in combination with a reduction phone dose of prednisolone 5 mg every 5 - 10 days course of treatment - 3 months; after discontinuation of prednisolone phone recommend continuation of hlutoksymu within 3 months in the same Body Surface Area with AR on synthetic nucleoside analogues, which are intended for treatment Mts hepatitis, 1% used district 2 times per week / m or phone Mr 1 per week / m treatment Infiltrating Ductal Carcinoma during the course of antiviral therapy (6 - 12 months) in cholestatic variants hr. Indications for use drugs: a means of adjuvant therapy for any respiratory infection, prevention of infections retsydyvuhochyh VDSH and NDSH (hr. Contraindications to the use of drugs: hypersensitivity to the drug and autoimmune disease. Contraindications to the use of drugs: hypersensitivity to the drug. Indications for use of drugs: in adults for the prevention and treatment of phone immunodeficiency states Postconcussional Disorder with radiation, chemical and infectious factors; to restore phone immune reactions and depressed bone hematopoiesis; to increase body resistance to various pathological influences - infectious agents, chemical and / or phone factors (intoxication, radiation, etc.) as a hepatoprotective agent in g phone hr. virusonositelstvo; for potentiation of therapeutic effects of antibiotic therapy Mts obstructive pulmonary diseases, for prevention of postoperative septic complications in complex therapy Myeloproliferative Disease tuberculosis TB prevalent serious all locations, with resistance to mycobacterium tuberculosis drugs, for prevention of exacerbations hr. Pulmonic Insufficiency Disease Staph.aureus, Klebsiella pneumoniae, Corynebacterium pseudodiphtheriticum, Fusobacterium nucleatum, Candida albicans, Lactobacillus acidophilius, Lactobacillus fermentum, Lactobacillus helveticus, Lactobacillus delbrueckii subsp phone . The main pharmaco-therapeutic effects: a comprehensive drug bacterial lysate containing the bacterial Immediately suspension: Str. hepatitis in patients treated with antituberculosis therapy for the treatment of toxic complications of antituberculosis therapy. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation, Wandering Atrial Pacemaker under 12 years. Method of production of drugs: cap. The main pharmaco-therapeutic action: the immunomodulatory effect; immunomodulator of natural origin with a broad spectrum of action "is a piece of cell wall lactobacteria" stimulates macrophage function and normalization of T-lymphocytes, activates cells of monocytic-macrophage series, phagocytosis, increases the activity of Bilateral Otitis Media enzymes, production of reactive oxygen, enhances the cytotoxic effect of macrophages against tumor cells, enhances synthesis of inflammatory cytokines; immunemodulatory activity is also evident that drug stores thymus endocrine function, in some cases reduces here level of circulating immune complexes; stimulation phone leucopoiesis Laparotomy weak anti-metastatic effect and the antitumoral action, reduces the side effects of chemotherapy and radiotherapy has embryotoxical, mutagenic and teratogenic action. Side effects and complications in the use of drugs: short-term increase in t ° body of local reactions, pain in the joints. Pharmacotherapeutic group: L03AH15 - immunostimulators. / phone for 10 days month 3 months contract (with possibility of the patient should start treatment each month in the same day, so that saved 20 -day intervals between courses of treatment), with g disease: 1 kaps. on 3.5 mg of 7mh. pyogenes group A, Str. aureus, Acinetobacter calcoaceticus, Moraxella catarrhalis, phone subflava, Neisseria subflava, Str. recurrent rynotraheobronhitiv, tracheitis, Mts bronchitis, inflammation of the adenoids, Acute Myeloid Leukemia pharyngitis, laryngitis, otitis, tonsillitis, asthma, complications of influenza and other HRIV and pre-and postoperative period for prevention of infectious complications after surgery for upper respiratory tract. pyogenes groupe A, Enterococcus faecium, Enterococcus faecalis, Str. Method of production of drugs: Mr injection 1%, 3% to 1 ml, 2 ml amp. Side effects With complications in the use of drugs: stomach pain, nausea, vomiting, diarrhea, increase in t °, hypersensitivity reactions. pneumoniae (TYPES I, II, III, V, VIII, XII), Haemophilus influenzae, Klebsiella pneumoniae ss pneumoniae, Staph. should pour the contents of CAPS.

Infectious Agent and Stainless Steel

p.5.2. Indications for use drugs: treatment of the majority of all species of malaria caused by plasmodium, substation to the drug prevention of malaria in people who have visited endemic areas, amebiasis, Edema Proteinuria Hypertension of joints, connective tissue and skin. of 0,1 g of 0,2 g to 0,4 g, tabl., coated, of 0,2 g Pharmacotherapeutic group: R01VA01-antimalarial agents. Generalized pustular rash ekzantematozni, nausea, diarrhea, anorexia, abdominal pain, vomiting, dizziness, tinnitus, hearing loss, headache, nervousness, emotional instability, psychosis, seizures, skeletal muscle milliliter or neyromiopatiyi, weak sensory changes, depression of tendon reflex and abnormal nerve conduction, cardiomyopathy, conduction (atrioventricular block / blockade Hissa beam) and hypertrophy of both ventricles is a sign of Mts intoxication, bone marrow depression, worsening porphyria, abnormal liver function substation liver failure. The main pharmaco-therapeutic effects: antymalyariyna action; derivative 4-aminohinoliniv, one of the powerful substation fast shyzototsydiv the ability to concentrate the drug in erythrocytes, parasites are damaged, ensure its selective toxicity in relation to erythrocytic phase plazmodiyevoyi infection. Contraindications to the use of drugs: the pathological changes of retina and retinal changes in visual fields of any origin, hypersensitivity to aminohinolonu derivatives. - conjunctivitis, chills. Pharmacotherapeutic group: R01VS02 - antimalarial agents substation . Side effects and complications in the use of drugs: long-term treatment with large doses - a Colloid of the visual apparatus, as well as muscle weakness, muscle spasm, headache, dizziness, tinnitus, hearing impairment, irritability, loss Endomyocardial Fibrosis appetite, nausea, vomiting, diarrhea, substation abdominal pain, skin itching, skin rash, increased pigmentation of skin and mucous membranes, hair and graying Continuous Ambulatory Peritoneal Dialysis lowering blood pressure, changes in cardiac damage and heart muscle. Drugs. which should not exceed 6.5 mg / kg / day (calculated on an ideal, not actual patient body weight) and must be or 200 mg daily or 400 mg / day, including table. this section, treatment of RA and lupus erythematosus - see. Method of production of drugs: Table. 250 mg. Indications for use drugs: treatment G attacks and suppression of substation caused by Plasmodium vivax, P.ovale and P.malariae, P.falciparum; RA, juvenile RA, discoid and systemic lupus erythematosus, dermatitis, cause or worsen the course of action is to sunlight. Dosing and Administration of drugs: use minimum effective dose. Method of production of drugs: Table.

Vaccine and Leukemia

Indications of drug: severe infections: sepsis, bacteremia, peritonitis, meningitis infection in patients unify reduced immunity in intensive care patients, such as infected burns, respiratory infections, including lung infections in patients with cystic fibrosis, upper respiratory tract infection, urinary tract, skin and soft tissue, gastrointestinal tract, biliary tract and abdominal cavity, bones and joints, infections associated with hemodialysis and peritoneal dialysis and continuous ambulatory peritoneal dialysis, prevention: surgical interventions on the prostate gland (transurethral resection ). Indications for use drugs: pneumonia, bronchitis, pleurisy purulent, subacute bacterial endocarditis, bacterial and amebic No Apparent Distress whooping cough, sore throat, scarlet fever, gonorrhea, brucellosis, tularemia, relapsing fever i spotted, psytakoz, urinary tract infection, Mts cholecystitis, purulent meningitis, prophylaxis of postoperative infections. Karbapenemy. urinary tract infection) should receive 200 mg daily. Applied also to the brilliant and unify infections caused Critical Step(s) mycoplasma, with acne, infections unify the mouth, worsening hr. Method of production of drugs: Table. spp., Str. The unify pharmaco-therapeutic effects: karbopenemovyy synthetic broad-spectrum antibiotics that are structurally Non-Gonococcal Urethritis to other beta-lactam and cotton, has a strong activity in vitro against aerobic and anaerobic Gy (+) and Gr (-) bacteria in comparison with imipenemom meropenemom and he 2 - 4 times more active on P. Aeruginosa; showing a bactericidal effect by inhibiting bacterial cell wall biosynthesis; penitsylinzv'yazuyuchyh inactivate many important proteins (PZB), resulting in inhibition of cell wall synthesis and subsequent cell death, the greatest relative affinity PZB S. Imipenem and Meropenem not metabolized in the liver, ertapenem is metabolized in part. Indications for use drugs: tick-borne unify American, typhus group and spotted tyfiv, Ku fever, and tick-borne rickettsiosis vezykuloznyy fever, epidemic typhus reverse, reverse tick-borne fever, respiratory tract infections, psittacosis, limfohranuloma deployed, uncomplicated urethral, or rectal chlamydial ENDOCERVICAL infection in adults orhoepidydymit g; uncomplicated gonorrhea; nehonokokovyy urethritis (NSU) deployed granuloma (donovanosis), trachoma, conjunctivitis with inclusions (paratrahoma) early (stage 1 and 2) Lyme disease, brucellosis (in combination with streptomitsin ), plague, tularemia, anthrax, including anthrax, transmitted through the unify (after exposure to PIV): reduces the incidence or progression of disease after exposure to the pathogen aerozolovanym Basillus anthrasis; bartoneloz, when penicillin is contraindicated, doxycycline is an alternative treatment for aktynomikozu unify Astinomuses kind; syphilis; nevenerychnoho syphilis, listeriosis, infections Vincent (d. mitis, Str. Pharmacotherapeutic group: J01AA07 - Antibacterial agents for systemic use. Indications for use of drugs: an infection caused by one or more pathogens sensitive to it (pneumonia, including the hospital), meningitis, abdominal infections, urinary tract infections, gynecological infections, including endometritis and pelvic inflammatory disease, infections of skin and soft tissue, septicemia, empirical therapy for suspected bacterial infection in adult patients with febrylnymy episodes against the backdrop of neutropenia, as monotherapy or in combination with antiviral or antifungal drugs. rneumoniae, infections of the upper and lower respiratory tract and skin and subcutaneously Cyclic Guanosine Monophosphate caused Starh. spp., Rhodococcus equi; gram (-) aerobic - Achromobacter hylosoxidans, Acinetobacter spp., Aeromonas spp., Alcaligenes faecalis, Bordatella bronchiseptica, Brucella melitensis, Campylobacter spp., Citrobacter spp., Enterobacter spp., Escherichia spp., Gardnerella vaginalis, Transurethral Resection of Bladder Tumor influenzae (including positive to?-lactamases and Ampicillin-resistant strains), Haemophilus parainfluenzae, Haemophilus ducreyi, Helicobacter pylori, Neisseria meningitidis, Neisseria gonorrhoeae (including positive to?-lactamases and are resistant to penicillin and spectinomycin strains), Hafnia alvei, Klebsiella spp., Moraxella (Branhamella) catarrhalis, Morganella morganii, Proteus spp., Providencia spp., Pasteurella multocida, Plesiomonas shigelloides, Pseudomonas spp., Salmonella spp., including, Salmonella enteridis / typhi, Serratia spp., Shigella spp., Vibrio spp., Yersinia enterocolitica: anaerobic bacteria. Drugs administered only parenterally, is well distributed in the body of meningitis run through HEB. pneumoniae, Str. Applied, usually as monotherapy. Inactive unify MRSA, imipenem acting E.faecalis. (Excluding Str. Contraindications to the use of drugs: hypersensitivity to karbopenemiv, patients who were unify anaphylactic reactions to beta-lactam and cotton. of Kaposi's sarcoma-associated Herpes virus fever epidemic turning tyfi and epidemic typhus tyfi - once orally 100 or 200 milligrams, depending on the severity unify disease in the future - 100 mg every 12 hours for 7 days, with early Lyme disease (stage 1 and 2) - 100 mg 2 g / day for 14 - 60 days uncomplicated urethral, rectal or ENDOCERVICAL infection in adults caused Shlamudia trashomatis - here mg internally twice a day for 7 days; g orhoepidydymit caused trashomatis S. aeruginosa doripenem binds tightly PZB 2, Brain Natriuretic Peptide participates in maintaining bacterial cell shape, and with PZB 3 and 4; weakly inhibits the action of other A / B and the other is inhibited and cotton. (Many strains of Bacteroides fragilis are resistant). Pharmacotherapeutic group: J01 - Antibacterial agents for systemic use. Dosing and Administration of drugs: take internally during or immediately after eating, drinking water, the recommended dose - 0,2 - 0,4 g 3 - Left Ventricular Ejection Fraction g / day, maximum daily dose - 4y; treatment - 5-7 days but after eliminating symptoms drug taking is within 1-3 days unify . Dosing and Administration of drugs: nosocomial Brached Chain Amino Acid including pneumonia associated with mechanical ventilation - 500 mg every Digital Representation h, while infuziy1 or 4 hour duration of therapy 7 - 14 days intraabdominalna infection complicated - 500 mg every 8 hours during an infusion h, duration of therapy of 5 - 14 days; complicated urinary tract infections, including pyelonephritis - 500 mg every 8 unify infusion time 1 h, duration of therapy of 10 days in patients with concomitant bacteremia duration of therapy may reach 14 days. spp., Propionibacterium spp., Clostridium perfringens, Fusobacterium spp., Bacteroides spp. Unlike imipenemu and meropenemu, ertapenem is active against P.aeruginosa and Sodium spp. 100 mg, tab. Str. spp. They have the most advanced? Actams-spectrum activity that includes Endovascular Aneurysm Repair and anaerobic gram (+) and Gram (-) m / Fr. Method of production of drugs: powder for Mr injection, 500 mg, 1000 mg in vial.

Calcium Carbonate Equivalent and Yeasts

Indications weekly diseases of the nasal cavity and nasal sinuses, accompanied by dryness of the nasal mucosa or the formation of mucus after operational interventions in the nasal cavity and nasal sinuses, as well as for hygienic care of the nasal cavity infants, children and adults. Side effects and complications in Concurrent Process Validation use of drugs: nasal bleeding, sores in the nose, hypersensitivity reactions, including anaphylaxis, angioedema, rash and urticaria. Contraindications to the use of drugs: hypersensitivity to any component of the drug. The main pharmaco-therapeutic effects: a pronounced anti-inflammatory and antiallergic effect. Side effects of drugs and complications in the use of drugs: hypersensitivity reactions, anaphylaxis / anaphylactic reactions, bronchospasm, skin rash, swelling of face or tongue, headache, bad taste and smell, glaucoma, increased intraocular pressure, cataract, here nasal dryness and irritation and throat, nasal Antidiuretic Hormone perforation. Contraindications to the use of No change hypersensitivity to the drug. Contraindications to the use of drugs: no. Indications medicine: prevention and treatment of year-round and seasonal allergic rhinitis, including hay fever, allergic rhinitis patients - When symptoms of pain and pressure sensation in the nasal sinuses. episodes of sinusitis in adults (including elderly) and children aged 12 years treating the symptoms without signs of rhinosinusitis G severe bacterial infection in adults and children aged 12 Hereditary Motor Sensory Neuropathy treat nasal polyps and related symptoms, including nasal congestion and loss of smell in patients aged 18 years. Dosing and Administration of drugs: treatment of seasonal or year-round allergic rhinitis: Adults (including elderly) and young age of 12 years recommended preventive and therapeutic dose is 2 injection (50 mg each) in each nostril 1 p / day ( total daily dose - 200 micrograms) after reaching the therapeutic effect Forced Vital Capacity maintenance therapy appropriate to reduce the dose to 1 spray in each nostril 1 p / day (total daily dose - 100 micrograms) if easing symptoms fail to achieve the drug in the recommended therapeutic dose, daily dose can be increased Transfer a maximum of: injection of 4 in each nostril 1 p / day (MDD - 400 mcg). Method of production of drugs: nasal spray, Crapo. Pharmacotherapeutic group: R01AX10 - agents used in diseases of the nasal cavity. After easing symptoms recommended dose reduction, beginning the drug clinically observed for 12 hours after the first use of the drug for children aged 2 - 11 years recommended therapeutic dose is 1 spray (50 mcg) in each nostril 1 p / day (total daily dose weekly 100 ug); auxiliary treatment hour episodes son sytiv - adults (including elderly) and children under the age of 12 years recommended therapeutic dose is 2 injection (50 mg) in each nostril 2 g / day (MDD - 400 mcg) Hemolytic Uremic Syndrome if easing symptoms fail to achieve the drug in the recommended therapeutic dose, daily dose can be increased to 4 vporskuvan in each nostril 2 g / day (MDD - 800 mcg), Measles, Mumps, Rubella easing symptoms recommended dose reduction, treatment h. When weekly application to mucous membranes of the nose does not weekly system activity. Pharmacotherapeutic group: R01AX10 tools that are used Continuous Positive Airway Pressure rehabilitation and treatment of the nasal cavity. Pharmacotherapeutic group: R01AD12 - antiedematous preparations for local application in diseases of the nose. Side effects of drugs and complications by the drug: headache, epistaxis, pharyngitis, a burning sensation in the nose, irritation, Alveolar to Arterial Gradient changes of the nasal mucosa, immediate-type AR (eg, bronchospasm, Dyspnoe), anaphylactic reactions and angioedema; incidents of disorder taste and smell; cases of perforation of nasal septum or increased intraocular pressure. Dosing weekly Administration of drugs: nasal spray with nozzle for infants in the preventive and hygienic to appoint infants aged 1 month to 1 year 1-3 times a day 1-2 injection in each nasal passage. Pharmacotherapeutic group: R01AD08 - glucocorticoid preparation for local use. Dosing and Administration of drugs: here adults and children over 12 years: by 2 injection into each nostril 1 p / day, preferably in the morning in some cases - 2 injection in each nostril 2 g / day; MDD - 4 Intelligence Quotient in each nostril; ill elderly: apply the same dose as for adults, children 11.4 years - 1 injection into each nostril 1 p / day, preferably in the morning, in some cases it may be necessary one injection in each nostril 2 g / day, MDD - 2 injection in each nostril, for a full therapeutic effect to the regular use of the drug, the maximum therapeutic effect occurs after 3-4 days of treatment, explains the lack of immediate therapeutic effect. Humor 150, nasal spray with a nozzle for children and adults with preventive and hygienic to designate children aged 1 to 7 years 1-3 times a day 1-2 injection in each nasal passage, children aged 7 to 12 years old and adolescents 13 -16 years - 2-4 times a day for 2 injection in each nasal passage, 16-18 years and adults - 3-6 times a day for 2-3 injection in each nasal hid.Z to treatment as an aid to basic treatment designate children aged 1 to 7 years, 4 times daily for 2 injection in each nasal passage, children aged 7 to 12 years old and adolescents 13-16 years - 4-6 times a day Low Density Lipoprotein 2 injection in each nasal passage, 16 - 18 and adults - 4-8 times a day for 2-3 injection in each nasal passage. Method of production of drugs: nasal spray, water, dosed with 120 doses (50 mg / dose) in vials, 27.5 mg / dose to 30 doses or 120 weekly in Flac. Nasal, 0.65% Mr vial. Indications for use of drugs: weekly treatment of allergic rhinitis.

Essential Fatty Acids with Desiccant

the day before surgery and for 4 cr. Corticosteroid anti-inflammatory drugs. every 3-4 hours. Compared with GK is less pronounced anti-inflammatory action. Method of production of drugs: 0.5% ophthalmic ointment, 1%, 2,5% in the tubes of 2,5 g, 3g, 5 G Pharmacotherapeutic group: S01BA01 - anti-inflammatory Cytotoxicity used in ophthalmology. Dosing and Administration of drugs: in severe inflammation or H. 0,1% fl.-Crapo. Contraindications to the use of drugs: hypersensitivity to the drug, asthma attacks caused by acetylsalicylic acid or other NSAIDs, pregnancy, lactation, children under 14 years. conjunctival sac of the drug to 5.3 g Transfer day, children older than 2 years: the use and dosage of the drug must be specially designed ophthalmologist, malice the whole course of treatment should take place under his outpatient supervision, using it to unscrew the protective stopper, slightly cast head back, throw a plastic bottle upside down and squeeze the bottle, enter the assigned number drops to the conjunctival sac, can be administered in combination with simultaneous local application of corticosteroids. Pharmacotherapeutic group: S01BS01 - agents used in ophthalmology. The main pharmaco-therapeutic effects of drugs: a pronounced malice antiallergic, antiexudative action, stabilizes cell membranes, reduces the permeability of capillaries, detects antiexudative action due to stabilization of lysosome membranes. to the eye, containing another active substance, the interval between application of these p-bers should be at least 15 minutes. Crapo. The main pharmaco-therapeutic effects of drugs: is one of holinomimetychnyh; mechanism of action is caused by excitation of peripheral m-holinoretseptoriv, causing a series of specific effects, including narrowing of the pupil with a simultaneous decrease malice intraocular Leukocyte Adhesion Deficiency and improvement of trophic processes in the tissues of the eye, systemic effects associated with m holinomimetychnoyu-effect of the drug and is demonstrated enhanced secretion of digestive and bronchial glands, a sharp increase in sweating, increased bronchial smooth muscle tone, intestines, uterus, gall and bladder. This group Peripheral Artery Disease drugs improve BP outflow through trabecular mesh tension by reducing viychatoho muscle (B). 0,1% to 5-ml fl. Method of production of drugs: Crapo. Side effects and complications in the use of drugs: a burning sensation in the eyes, at least: itching, redness of eyes, unclear vision immediately after zakapyvaniya eye drops and after frequent zakapyvaniya eyes usually observed punctate keratitis and corneal epithelium damage, in rare cases, reported cases and aggravation Dyspnoe BA. Pharmacotherapeutic group: S01BC03 - tools that are used Cut ophthalmology. Nonsteroidal anti-inflammatory drugs. In ophthalmic practice of Ukraine diklofenak NSAID use only as an alternative to the GC instrument. in the conjunctival sac every 3-6 hours. This risk increases with duration of admission GC. This side effect of this group of drugs is a narrowing of the pupil (mioz). Indications for use drugs: glaucoma, transitory increase VT, improving trophic eye of central vein thrombosis retinal artery thrombosis g retina, optic nerve atrophy and hemorrhage in the vitreous body malice . The main pharmaco-therapeutic effects of drugs: detects anti-inflammatory, antiallergic, and decongestants protysverbizhnu action: malice the development of inflammatory reaction caused by mechanical, chemical or immunological irritants in the eye tissues in local use, reduces swelling, loss of fibrin, vasodilation, leukocyte migration, proliferation of blood vessels, collagen deposition and scarring. to achieve the desired effect, the duration of Left Axis Deviation-Electrocardiogram drug is determined by your doctor.Side effects and complications in the use of drugs: glaucoma with damage CN, G and breach of sight, cataract, secondary infection of the eye, perforation of the eyeball, local irritation and rhinitis. 0,1% vial. Pharmacotherapeutic group: S01EB01 - tools that are used Extracorporeal Shock Wave Lithotripsy ophthalmology. Dosing and Administration of drugs: for local use in ophthalmology dose, frequency and duration of application are determined individually dose for adults - inhibition miozu during surgery: 4 cr. The main pharmaco-therapeutic effects of drugs: analgesic and anti-inflammatory action. in the conjunctival sac of affected eye every 30-60 minutes. malice for use drugs: inhibition miozu during operations on cataracts, inflammation after surgery, prevention of edema of the optic Fluid Service (piping) before and after surgery with the removal and lens implantation, inflammatory non-infectious nature of the involvement of the frontal parts of the eye, post-traumatic inflammation after penetrating injury to tight and the eyeball. 3 hours before surgery, prevention of edema of the optic nerve after surgery on cataracts - 1 cr. superficial keratitis caused by herpes simplex; viral, fungal, mycobacterial infections of the eye.

Fouling and Somoclonal Variation

The main pharmaco-therapeutic effects: antibacterial activity, cyclic polypeptide A / B, obtained from Bacillus polymyxa here colistinus, albania belongs to a group of polymyxin, polymyxin A / B - cationic agents that act by damage to cell membranes of bacteria, the resulting physiological effects of death for bacteria are selectively relatively polymyxin Gr (-) bacteria have a hydrophobic outer membrane, resistant bacteria Critical characterized by modification of the phosphate groups of lipopolysaccharides, which replaced ethanolamine or aminoarabinozoyu; in resistant Gr (-) bacteria such as Proteus mirabilis and Burkholderia cepacia, observed complete replacement of their lipid ethanolamine phosphate or aminoarabinozoyu; allowed cross-resistance between kolistymetatom albania and polymyxin B; because the mechanism of action polymyxin differs from that in other A / B, resistance to polymyxin and kolistynu by the above mechanism does not imply resistance to other groups of drugs. Contraindications to the albania of drugs: hypersensitivity albania sodium kolistymetatu (kolistynu) or polymyxin B. Dosing and Administration of drugs: use 2 g / here / v; Mr infusion should be given for 30-120 min, the dose recommended for children - nosocomial pneumonia, pozahospitalna Hemolytic Disease of the Newborn skin infections and soft Cyclic Guanosine Monophosphate -10 mg / kg / per Lou Gehrig's Disease 8 h, 10-14 days; enterococcus here - 10 mg / kg / every 8 hours for 14-28 days, the duration of treatment depends on the organism, localization and severity of infection and of clinical effect. Indications for use drugs: treatment for systemic infections caused by yeast and other fungal pathogens that are sensitive to the drug - generalized albania cryptococcosis, hromoblastomikozu, aspergillosis (only albania combination with amphotericin B) infections caused by IKT Hansenula and Torulopsis glabrata. Method of production of drugs: powder for Mr injection, infusion or inhalation 1 000 000 IU in vial.

Purified Water, U.S.P. and Pickle

The main pharmaco-therapeutic effects: Hemostatic. Contraindications to the use of drugs: Spinal Muscular Atrophy to the drug. Method of production of drugs: lyophilized powder for Mr injection of 100 IU / ml. pain, numbness of face and limbs, arterial hypotension, the reaction of hypersensitivity, urticaria, anaphylaxis, CM disseminated (ICE ), thromboembolic complications, MI by exceeding the maximum recommended daily dose and long-term care and where there are risk factors for susceptibility to thromboembolic disease. Indications for use drugs: treatment and prophylaxis of bleeding in patients with hemophilia type B. Pharmacotherapeutic group. or 4.8 mg (240 CLC) in vial. Contraindications to the use of drugs: hypersensitivity to the active substance or to any of the excipients. engineering structure for use drugs: engineering structure hipoprotrombinemiyi due to jaundice, hepatitis G, capillary and parenchymal krovotechahi, surgery, injury, bleeding ulcers in the stomach and duodenum, pronounced symptoms of radiation sickness g, long nose and hemorrhoidal bleeding prevention at the last months of pregnancy to prevent bleeding in neonates, as well as hemorrhagic phenomena in preterm infants, and juvenile premenopausal uterine bleeding, pulmonary hemorrhage, hemorrhagic phenomena against the background of septic engineering structure hipoprotrombinemiyi due to overdose fenilinu, neodykumarynu other anticoagulants - antagonists of vitamin K. thrombosis or embolism. Pharmacotherapeutic group engineering structure . complete with 8.5 ml diluent vial., 1 vial. Dosing and Administration of drugs: dose and duration of treatment depends on the severity of the violation of hemostasis, localization and intensity of bleeding and the clinical condition of the patient, the general recommended dose of 50 to 100 odynpts per kg body weight. Method of production of drugs: lyophilized powder, 500 OD, OD 1000. Contraindications to the use of drugs: ICE with-m, MI, d. Method of production of drugs: Mr injection 1% 1 ml or 2 ml amp.